Vosoritide Treatment in Children with Hypochondroplasia: Three-Year Results from a Phase 2 Extension Trial
Variant / mechanism
C-type natriuretic peptide analog (vosoritide), given by daily subcutaneous injection
Summary
Vosoritide, a C-type natriuretic peptide analog approved for achondroplasia, was evaluated in children with hypochondroplasia in a phase 2 trial (NCT04219007), whose three-year extension is reported here. After a 6-month observation period and 12 months of daily treatment (15 μg/kg/day subcutaneously), only participants whose annualized growth velocity had increased by more than 1.6 cm/year over baseline could continue in an open-label extension; thirteen children completed three years of treatment. Mean height SDS increased by 0.72 SD from Day 1 to Year 3, reaching −2.64 ± 0.79 SD on CDC charts, with a similar gain on hypochondroplasia-specific charts (0.83 SD). Mean growth velocity rose from 4.27 cm/year at baseline to 7.24 cm/year at Year 1 and remained above baseline at Year 3 (6.13 cm/year), with no new safety concerns.
Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.
Analysis
The growth benefit is sustained at three years, but in selected responders: the extension, restricted to children who gained more than 1.6 cm/year in the first year, prevents these figures from being applied to all affected children. Thirteen patients without a control group are not enough to support an indication, and a controlled trial is still needed before extending use beyond achondroplasia.
Analysis by Dr Thibaut Benquey
Why this score?
Clinical impact: 2/3 · Evidence strength: 1/3 · Novelty: 1/2 · Sample size: 1/1 · Publication status: 1/1 → Total: 6/10
Keywords
Every Wednesday · Annotated selection · Free · Unsubscribe anytime